









市场行情
/
股票
/
nasdaq-gild
/

吉利德科学

GILD

124.700USD

-0.970-0.77%

收盘 12/26, 16:00（美东）报价延迟15分钟

154.88B总市值

19.15市盈率 TTM



吉利德科学

124.700

-0.970-0.77%

概览公司财务分析

概览

公司

财务

分析

关于吉利德科学公司

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.

吉利德科学简介



公司代码GILD

公司名称Gilead Sciences Inc

上市日期Jan 22, 1992

CEOO'Day (Daniel P)

员工数量17600

证券类型Ordinary Share

年结日Jan 22

公司地址333 Lakeside Dr

城市FOSTER CITY

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94404-1147

电话16505743000

网址https://www.gilead.com/

公司代码GILD

上市日期Jan 22, 1992

CEOO'Day (Daniel P)

吉利德科学公司高管



名称

名称/职务

职务

持股

持股变动

Ms. Johanna Mercier

Chief Commercial Officer

79.97K

-3.62%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

26.06K

+6.18%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

11.75K

+14.82%

Ms. Kelly A. Kramer

Independent Director

1.34K

Ms. Erin Burkhart

Senior Vice President, Principal Accounting Officer, Controller

Dr. Dietmar P. Berger, M.D., Ph.D.

Chief Medical Officer

Mr. Andrew D. (Andy) Dickinson

Chief Financial Officer

Mr. Harish Manwani

Independent Director

Dr. Ted W. Love, M.D.

Independent Director

Mr. Javier J. Rodriguez

Independent Director

名称

名称/职务

职务

持股

持股变动

Ms. Johanna Mercier

Chief Commercial Officer

79.97K

-3.62%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

26.06K

+6.18%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

11.75K

+14.82%

Ms. Kelly A. Kramer

Independent Director

1.34K

Ms. Erin Burkhart

Senior Vice President, Principal Accounting Officer, Controller

Dr. Dietmar P. Berger, M.D., Ph.D.

Chief Medical Officer

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

业务USD

名称

营收

占比

Biktarvy

3.53B

49.84%

Descovy

653.00M

9.22%

Yescarta

393.00M

5.55%

Genvoya

378.00M

5.34%

Trodelvy

364.00M

5.14%

其他

1.76B

24.91%

地区USD

名称

营收

占比

United States

5.00B

70.59%

Europe

1.17B

16.51%

Other Locations

792.00M

11.18%

业务

地区

业务USD

名称

营收

占比

Biktarvy

3.53B

49.84%

Descovy

653.00M

9.22%

Yescarta

393.00M

5.55%

Genvoya

378.00M

5.34%

Trodelvy

364.00M

5.14%

其他

1.76B

24.91%

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

9.54%

BlackRock Institutional Trust Company, N.A.

5.86%

State Street Investment Management (US)

4.76%

Fidelity Management & Research Company LLC

4.34%

Capital World Investors

3.64%

其他

71.86%

持股股东

占比

The Vanguard Group, Inc.

9.54%

BlackRock Institutional Trust Company, N.A.

5.86%

State Street Investment Management (US)

4.76%

Fidelity Management & Research Company LLC

4.34%

Capital World Investors

3.64%

其他

71.86%

股东类型

持股股东

占比

Investment Advisor

54.42%

Investment Advisor/Hedge Fund

25.61%

Pension Fund

2.86%

Research Firm

2.81%

Hedge Fund

2.00%

Bank and Trust

1.90%

Sovereign Wealth Fund

1.73%

Insurance Company

0.15%

Venture Capital

0.10%

其他

8.41%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

3433

1.13B

91.16%

+23.58K

2025Q2

3388

1.12B

90.01%

-12.02M

2025Q1

3442

1.12B

90.14%

-10.49M

2024Q4

3313

1.12B

90.13%

+4.63M

2024Q3

3207

1.10B

88.48%

-11.56M

2024Q2

3188

1.10B

88.24%

-14.37M

2024Q1

3196

1.10B

88.13%

-22.04M

2023Q4

3252

1.11B

88.75%

-8.79M

2023Q3

3190

1.10B

88.14%

-23.58M

2023Q2

3196

1.10B

88.02%

-11.22M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

118.78M

9.57%

+1.87M

+1.60%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

70.80M

5.71%

+138.89K

+0.20%

Jun 30, 2025

State Street Investment Management (US)

59.19M

4.77%

-335.51K

-0.56%

Jun 30, 2025

Fidelity Management & Research Company LLC

53.76M

4.33%

+2.55M

+4.98%

Jun 30, 2025

Capital World Investors

46.30M

3.73%

-7.24M

-13.53%

Jun 30, 2025

Dodge & Cox

30.82M

2.48%

-1.88M

-5.74%

Jun 30, 2025

Capital Research Global Investors

31.10M

2.51%

-23.51M

-43.06%

Jun 30, 2025

Geode Capital Management, L.L.C.

29.21M

2.35%

+727.51K

+2.55%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

25.46M

2.05%

-89.95K

-0.35%

Aug 31, 2025

Wellington Management Company, LLP

37.53M

3.02%

+10.17M

+37.18%

Jun 30, 2025

持股ETF



更新时间: 12月5日周五

机构名称

占比

VanEck Biotech ETF

12.54%

ProShares Ultra Nasdaq Biotechnology

8.6%

Invesco Nasdaq Biotechnology ETF

8.54%

iShares Biotechnology ETF

7.24%

Simplify Health Care ETF

7.21%

Invesco Pharmaceuticals ETF

5.11%

Invesco Biotechnology & Genome ETF

5.08%

ProShares Nasdaq-100 Dorsey Wright Momentum ETF

4.62%

First Trust NASDAQ Pharmaceuticals ETF

4.12%

Tema Heart & Health ETF

3.95%

VanEck Biotech ETF

占比12.54%

ProShares Ultra Nasdaq Biotechnology

占比8.6%

Invesco Nasdaq Biotechnology ETF

占比8.54%

iShares Biotechnology ETF

占比7.24%

Simplify Health Care ETF

占比7.21%

Invesco Pharmaceuticals ETF

占比5.11%

Invesco Biotechnology & Genome ETF

占比5.08%

ProShares Nasdaq-100 Dorsey Wright Momentum ETF

占比4.62%

First Trust NASDAQ Pharmaceuticals ETF

占比4.12%

Tema Heart & Health ETF

占比3.95%

分红派息



近5年累计派现 18.49B 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

Oct 30, 2025

GILD.NB Final Cash Dividend of gross USD 0.79 paid on Dec 30, 2025 going ex on Dec 15, 2025

Dec 15, 2025

Dec 30, 2025

Dec 15, 2025

Aug 07, 2025

GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Sep 29, 2025 going ex on Sep 15, 2025

Sep 15, 2025

Sep 29, 2025

Sep 15, 2025

Apr 24, 2025

GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Jun 27, 2025 going ex on Jun 13, 2025

Jun 13, 2025

Jun 27, 2025

Jun 13, 2025

Feb 11, 2025

GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025

Mar 14, 2025

Mar 28, 2025

Mar 14, 2025

Nov 12, 2024

GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024

Dec 13, 2024

Dec 30, 2024

Dec 13, 2024

Aug 13, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024

Sep 13, 2024

Sep 27, 2024

Sep 13, 2024

Apr 26, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024

Jun 14, 2024

Jun 27, 2024

Jun 14, 2024

Feb 06, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Mar 28, 2024

Mar 14, 2024

Nov 08, 2023

GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023

Dec 15, 2023

Dec 28, 2023

Dec 14, 2023

Aug 07, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023

Sep 15, 2023

Sep 28, 2023

Sep 14, 2023

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

吉利德科学的前五大股东是谁？



吉利德科学的前五大股东如下：
The Vanguard Group, Inc.持有股份：118.78M，占总股份比例：9.57%。
BlackRock Institutional Trust Company, N.A.持有股份：70.80M，占总股份比例：5.71%。
State Street Investment Management (US)持有股份：59.19M，占总股份比例：4.77%。
Fidelity Management & Research Company LLC持有股份：53.76M，占总股份比例：4.33%。
Capital World Investors持有股份：46.30M，占总股份比例：3.73%。